Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCORD: Runcaciguat in CKD with Comorbidities
NCT04507061Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Runcaciguat with Placebo (2 arms). Primary endpoint: Change in Urinary Albumin-to-Creatinine Ratio at Day 57. Started Sep 2020; status: completed.
02
Drugs
runcaciguat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04507061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507061.